OCEA: Rega marang dodolan Ocean Bio
Ocean Biomedical, Inc. (OCEA) is developing a closed patent loop to combat malaria and cancer. This chart on GURU.Markets shows that the price-to-sales ratio has reached the metric. The business model relies on the commercialization of university research and the production of vaccines. However, a lack of internal revenue and the depletion of reserves force the company to regularly seek third-party investment.
Rincian analitis perusahaan Ocean Bio (OCEA)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- indikator beban kredit lan likuiditas emiten:
Utang marang Modal Ocean Biomedical, Inc.|OCEA - Utang jangka dawa marang modal|Utang jangka cendhak marang modal Ocean Biomedical Corp|OCEA - Utang perusahaan|Rasio utang marang nilai buku Ocean Bio|OCEA - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Ocean Biomedical|Likuiditas cepet oceanbiomedical.com
- data bathi lan kelipatan valuasi:
OCEA - Bathi resik|Prakiraan bathi perusahaan Ocean Biomedical, Inc.|OCEA - Rasio rega marang bathi|Rasio prakiraan rega marang bathi Ocean Biomedical Inc|OCEA - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Ocean Bio|OCEA - Bathi operasional EBITDA|Bathi resik saben siji saham sajrone rolas wulan pungkasan Ocean Biomedical|OCEA - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan oceanbiomedical.com|OCEA - Wutah bathi ing taun lumaku|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Ocean Biomedical, Inc.
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:oceanbiomedical.com (OCEA)
Analyzing the scale of Ocean Biomedical, Inc. (OCEA) through changes in the price-to-sales ratio allows for a comparison of the business's market value with actual sales volume. This metric links market capitalization to revenue and debt load, revealing asset overheating or liquidity risks, which is critical for biopharmaceuticals amid sanction threats to raw material supply chains and the complexities of foreign patent protection.
Karo sapa Ocean Biomedical, Inc. saingan
argenx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (BioNTech)|Abivax Pharma (ABVX) - Rega marang dodolan|ADMA - Rasio rega marang pendapatan|Rega marang dodolan Protagonist Corp|IMVT: Multiplikator P/S|Kapitalisasi marang pendapatan kiniksa.com|GRFS (Grifols) - Multiplikator P/S|Rega marang dodolan Adaptive Biotech ADPT|Multiplikator P/S CLDX|Multiplikator P/S Aurinia Corp (AUPH)|Rasio rega marang pendapatan BioCryst BCRX|VERA: Rasio kapitalisasi marang pendapatan|DNTH: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan PHVS (Pharvaris NV)|ABCL: Multiplikator P/S|TRML (Tourmaline) - Rasio rega marang pendapatan|PGEN (Precigen, Inc.) - Multiplikator P/S|pharming.com (PHAR) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Nektar Therapeutics Inc. (NKTR)|UPB - Rega marang dodolan|Rasio rega marang pendapatan Zenas Biopharma, Inc. ZBIO|IMNM - Kapitalisasi marang pendapatan|Gossamer Bio, Inc. - Multiplikator P/S|Rega marang dodolan kalvista.com|SEPN: Multiplikator P/S|Rasio kapitalisasi marang pendapatan PVLA|SVRA (Savara Corp) - Multiplikator P/S|Rigel Corp (RIGL) - Koefisien rega marang pendapatan|Multiplikator P/S ANAB|Kapitalisasi marang pendapatan astriatx.com ATXS|Multiplikator P/S ENGN (enGene)|Multiplikator P/S RAPT Therapeutics Inc. RAPT|JBIO - Rasio rega marang pendapatan|ACRS: Rasio rega marang pendapatan|KYTX (Kyverna Therapeutics) - Kapitalisasi marang pendapatan|tizianalifesciences.com - Rasio kapitalisasi pasar marang pendapatan|CABA (Cabaletta Bio) - Multiplikator P/S|Ventyx Biosciences Inc. (VTYX) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Theratechnologies Inc (THTX)|Avalo Therapeutics Inc - Rasio kapitalisasi marang pendapatan|Multiplikator P/S ELDN (Eledon Pharmaceuticals)|AGEN - Kapitalisasi marang pendapatan|CLYM: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Zura Bio Ltd ZURA|aTyr (ATYR) - Rasio rega marang pendapatan|Rega marang dodolan Adagene Inc. (ADAG)|IMA (ImageneBio) - Multiplikator P/S|Kapitalisasi marang pendapatan Shattuck Therapeutics (STTK)|Multiplikator P/S EQ|CNTB - Rega marang dodolan|Multiplikator P/S IMUX (Immunic)|Multiplikator P/S Atara Biotherapeutics, Inc. ATRA|IFRX - Rasio rega marang pendapatan|Rasio rega marang dodolan XFOR|ACET: Multiplikator P/S|Celularity - Rasio kapitalisasi pasar marang pendapatan|INMB (INmune Bio Corp) - Multiplikator P/S|Multiplikator P/S Barinthus Biotherapeutics Corp|Rasio rega marang pendapatan Kezar Life Sciences (KZR)|SABS (sabbiotherapeutics.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Akari Therapeutics Plc AKTX|ENLV - Kapitalisasi marang pendapatan|Q32 Bio Corp - Multiplikator P/S|GOVX - Multiplikator P/S|EDSA (Edesa Biotech, Inc.) - Kapitalisasi marang pendapatan|ibioinc.com - Rasio kapitalisasi pasar marang pendapatan|CARM (Carisma Therapeutics Inc) - Multiplikator P/S|XTL Biopharmaceuticals Ltd (XTLB) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Bolt Biotherapeutics (BOLT)|Kapitalisasi marang pendapatan hcwbiologics.com HCWB|Rasio rega marang pendapatan Aptevo Therapeutics Inc. APVO|AIM - Kapitalisasi marang pendapatan|ADTX: Kapitalisasi marang pendapatan|GRI - Multiplikator P/S|XORTX (XRTX) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan HIND|REVB (Revelation Biosciences) - Multiplikator P/S|Rega marang dodolan indaptusrx.com INDP|Rasio rega marang pendapatan Scinai Immunotherapeutics Ltd. (SCNI)|CALI - Rega marang dodolan|Multiplikator P/S AFMD (Affimed N.V.)|ALLK - Kapitalisasi marang pendapatan|HOOKIPA - Multiplikator P/S|Rega marang dodolan IGM Biosciences, Inc.|ITOS: Multiplikator P/S|TC BioPharm (Holdings) Plc (TCBP) - Multiplikator P/S|Rasio rega marang pendapatan Third Harmonic Bio, Inc
